For indicated medication in ovarian cancer
-For off-label medication in breast, pancreatic & prostate cancer and other solid tumours.
It has now been proven by a plethora of clinical studies that about 50% of ovarian cancer patients could benefit from the administration of PARP inhibitors. These include patients with:
Since 2014, four PARP inhibitors (PARPi) have been approved by the FDA: Olaparib, Niraparib, Rucaparib, and Talazoparib. Their administration has been approved for 4 types of cancer: ovarian, prostate, pancreatic and breast cancer.
HRD (Homologous Recombination Deficiency) means the inability of the cell to repair its damage through the homologous recombination pathway. The presence of genomic instability is indicative of the HR pathway insufficiency.
Three biological parameters ('genomic scars') are used to calculate it:
What types of cancer does it cover?
The RediScore® test is recommended primarily in all patients with ovarian cancer, but also where PARP inhibitor therapy is under investigation for treatment or maintenance of the patient.
What is the turnaround time for my results?
The results are delivered in 15 working days
What type of sample is required for the test?
For the Rediscore test we need paraffin blocks from the tumor or otherwise uncolored paraffin sections coated on slides.
Is the test covered by any public/private insurance?
Fore cost coverage and related information, please contact the secretariat here.
How do I make the payment for the test?
Payment can be made by bank transfer or debit/credit card.
How I send the sample and receive the results?
Regarding the receipt of the sample, please contact the secretariat. The results are shared with your doctor and with you via email.
Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.
*To complete the test, you are required to complete and send the Consent form that you will find on the link below.